EcoR1 Capital LLC Purchases New Holdings in Evolus, Inc. $EOLS

EcoR1 Capital LLC purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 675,000 shares of the company’s stock, valued at approximately $4,489,000. Evolus accounts for approximately 0.2% of EcoR1 Capital LLC’s portfolio, making the stock its 24th largest position. EcoR1 Capital LLC owned 1.04% of Evolus at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Rhumbline Advisers lifted its position in Evolus by 2.0% during the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after acquiring an additional 1,657 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Evolus by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after acquiring an additional 1,838 shares during the period. Invesco Ltd. lifted its position in Evolus by 7.5% during the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock valued at $316,000 after acquiring an additional 2,383 shares during the period. Larson Financial Group LLC lifted its position in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares during the period. Finally, Quantbot Technologies LP lifted its position in Evolus by 10.0% during the 3rd quarter. Quantbot Technologies LP now owns 32,692 shares of the company’s stock valued at $201,000 after acquiring an additional 2,961 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Stock Performance

Shares of Evolus stock opened at $6.74 on Thursday. The stock has a market capitalization of $443.90 million, a PE ratio of -10.06 and a beta of 1.34. Evolus, Inc. has a 52-week low of $3.86 and a 52-week high of $10.20. The company has a 50-day simple moving average of $5.87 and a two-hundred day simple moving average of $5.55.

Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. During the same period in the previous year, the business earned ($0.30) earnings per share. As a group, equities research analysts forecast that Evolus, Inc. will post -0.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on EOLS. BTIG Research reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Evolus presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 13,669 shares of Evolus stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $64,927.75. Following the completion of the transaction, the insider directly owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. The trade was a 2.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.00% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.